South America's shift toward synthetic drugs poses urgent overdose crisis

South America is experiencing a significant shift in its illicit drug landscape, with synthetic drugs rapidly replacing traditional substances like cocaine and alcohol. This study examines data from Brazil, Chile, and Colombia to document the emergence of three major drug movements: non-prescribed synthetic opioids (including fentanyl and nitazenes), ketamine, and Tusi ("pink cocaine")—a mixture typically containing ketamine and MDMA. While cannabis has historically dominated South American drug use alongside cocaine, these new synthetic substances are rapidly gaining ground, particularly among youth and nightclub attendees. The research highlights a critical public health challenge: these synthetic drugs carry significantly higher overdose risks due to their unpredictable composition and potency.

The findings reveal alarming trends across the three countries. Brazil and Chile have documented increases in non-prescribed opioid use, with Brazil discovering illicit fentanyl seizures and evidence of nitazene production. Colombia, despite historically lower opioid use, has found fentanyl analogs contaminating ketamine and MDMA samples, multiplying the health risks for users unaware of what they're consuming. Tusi's rapid expansion is particularly concerning because its composition varies dramatically from batch to batch, making overdose prevention extraordinarily difficult. The convergence of traditional drugs like cannabis and cocaine with potent synthetic opioids and novel psychoactive substances creates a compounding crisis that current public health infrastructure is unprepared to handle.

The study emphasizes that South America lacks the foundational infrastructure to address this emerging crisis. The region has minimal opioid agonist therapy coverage, limited naloxone access, and underdeveloped harm reduction systems—critical tools for preventing overdose deaths. The authors call for urgent action: strengthened regional surveillance, enhanced toxicological monitoring, robust drug-checking services, and coordinated international public health responses. Without rapid intervention, the synthetic drug phase could mirror opioid crises seen in North America and Europe, creating a devastating public health emergency across the continent.